Should I Buy ZURA? ZURA 2026 Analysis

Should You Buy Zura Bio Ltd (ZURA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

6.050

1 Day change

1.17%

52 Week Range

6.630

Analysis Updated At

2026/01/26

Zura Bio Ltd (ZURA) is not a strong buy for a beginner, long-term investor at the moment. While the technical indicators show bullish momentum and analysts have a positive outlook with a high price target, the company's financial performance is weak, with declining net income and EPS. Additionally, there are no significant trading trends or strong proprietary trading signals to support immediate action. The stock may be worth monitoring for future developments, but it is not an optimal buy right now for the given investor profile.

Technical Analysis

The stock shows bullish momentum with MACD positively expanding and moving averages (SMA_5 > SMA_20 > SMA_200) in a bullish alignment. RSI is neutral at 74.869, and the stock is trading near its R1 resistance level of 6.346 in pre-market. However, there is no strong indication of a breakout or immediate upward movement.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have initiated coverage with a Buy rating and a price target of $18, citing strong conviction in tibulizumab's potential in key medical areas. The recent appointment of a new CEO may bring fresh leadership and strategic direction.

Neutral/Negative Catalysts

The company's financial performance is weak, with declining net income (-12.66% YoY) and EPS (-19.23% YoY). Additionally, there are no significant hedge fund, insider, or congress trading trends to indicate strong institutional or political interest.

Financial Performance

In Q3 2025, Zura Bio reported no revenue growth (0% YoY), a net income loss of -$20.037 million (-12.66% YoY), and a decline in EPS to -0.21 (-19.23% YoY). Gross margin remained at 0%. The financials indicate a lack of profitability and growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Clear Street initiated coverage with a Buy rating and a price target of $18, citing strong conviction in the company's lead drug candidate and its potential to set new standards in its target markets.

2 Analyst Rating

Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 16.5 USD with a low forecast of 15 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 5.980

Low

Averages

16.5

High

Current: 5.980

Low

Averages

16.5

High

Clear Street

NULL

Buy

initiated

$18

AI Analysis

2025-11-12

Reason

Clear Street

Price Target

$18

AI Analysis

2025-11-12

initiated

NULL

Buy

Reason

Clear Street initiated coverage of Zura Bio with a Buy rating and $18 price target. The firm said he rating reflects "strong conviction" in tibulizumab's ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.

H.C. Wainwright

Neutral

downgrade

$3 -> $2

2025-08-19

Reason

H.C. Wainwright

Price Target

$3 -> $2

2025-08-19

downgrade

Neutral

Reason

H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in potentially dilutive shares outstanding.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZURA

Unlock Now

ZURA Should I Buy

ZURA Should I Buy

Should You Buy Zura Bio Ltd (ZURA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch